Iobenguane I-123 - GE Healthcare

Drug Profile

Iobenguane I-123 - GE Healthcare

Alternative Names: 123I-Iobenguane; 123I-mIBG; 3-iodobenzylguanidine I-123; AdreView; Iobenguane I123 Injection; Metaiodobenzylguanidine I-123 - GE Healthcare

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; University of Ottawa Heart Institute
  • Class Antineoplastics; Iodobenzenes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Neuroendocrine tumours
  • Registered Neuroblastoma

Most Recent Events

  • 01 Jan 2016 GE Healthcare initiates enrolment in a phase-III trial for Heart failure (Diagnosis) in USA (IV) (NCT02656329)
  • 01 Dec 2013 Phase-III clinical trials for Heart failure (Diagnosis) in Canada (IV) (NCT02043522)
  • 22 Mar 2013 US FDA approves iobenguane I123 for Diagnostic imaging of Heart Failure in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top